FLGT
Fulgent Genetics, Inc.
FLGT trails on the overall score without a compensating advantage in the available component scores.
OSCR
Oscar Health, Inc.
OSCR has the edge over FLGT overall, supported by stronger fundamentals and lower modeled downside.
FLGT Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Under pressure | |
| Strong |
FLGT's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
FLGT PE Valuation
FLGT has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
FLGT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Growth | |
| Weakening | |
| Limited | |
| High |
Analysts expect FLGT's losses to grow, with revenue growing.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over FLGT on the outlook, with more favorable earnings and profitability expectations.
FLGT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.10 | -$1.71 |
| Q2 2026 | -$2.83 | -$1.17 |
| Q1 2026 | -$2.40 | -$1.07 |
| Q4 2025 | -$1.97 | -$0.56 |
| Q3 2025 | -$1.39 | +$4.12 |
| Q2 2025 | -$1.66 | +$3.81 |
| Q1 2025 | -$1.33 | +$4.23 |
| Q4 2024 | -$1.41 | +$4.22 |
FLGT lost $3.10 per share over the past year, and its loss has widened in each of the last four quarters.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over FLGT on earnings quality, reporting a profit while its opponent remains loss making.
FLGT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $90.4M | +7.5% |
| Q2 2026 | $85.4M | +4.4% |
| Q1 2026 | $71.1M | -3.2% |
| Q4 2025 | $83.3M | +9.3% |
| Q3 2025 | $84.1M | +17% |
| Q2 2025 | $81.8M | +15% |
| Q1 2025 | $73.5M | +14% |
| Q4 2024 | $76.2M | +8.1% |
FLGT's revenue is recovering but still below its 2021 peak: $90M last quarter, up 7.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -25% | -6.7 points |
| Q2 2026 | -42% | -18 points |
| Q1 2026 | -49% | -22 points |
| Q4 2025 | -43% | -22 points |
| Q3 2025 | -18% | +5.5 points |
| Q2 2025 | -24% | +2.5 points |
| Q1 2025 | -27% | +6.8 points |
| Q4 2024 | -21% | +193 points |
FLGT's operating margin was −25% last quarter, down 6.7 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over FLGT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over FLGT on profitability, with a higher operating margin.
FLGT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $107.4M | +2025% |
| Q2 2026 | -$27.6M | +$9.4M |
| Q1 2026 | $1.9M | +$11M |
| Q4 2025 | -$83.1M | -491% |
| Q3 2025 | $5.1M | +$40.1M |
| Q2 2025 | -$37M | -$28.3M |
| Q1 2025 | -$9.1M | -385% |
| Q4 2024 | $21.2M | +80% |
FLGT's free cash flow was −$1M over the past year, against −$20M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over FLGT on cash generation, producing positive trailing cash flow while its opponent burns cash.
FLGT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.2% | -343K shares |
| 1 year | -10% | -3.1M shares |
| 3 years | -7.8% | -2.4M shares |
| 5 years | -11% | -3.5M shares |
| Available history | +48% | +9M shares |
FLGT has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $251,000 |
| Q2 2026 | $23.8M |
| Q1 2026 | $40.1M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.2M |
| Q1 2025 | $8.7M |
| Q4 2024 | — |
FLGT spent $64M buying back its own shares over the past year, about six times what it spent the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
FLGT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2022 | -0.4x | Net Cash |
| Q3 2022 | -0.4x | Net Cash |
| Q2 2022 | -0.2x | Net Cash |
| Q1 2022 | -0.6x | Net Cash |
| Q4 2021 | -0.2x | Net Cash |
| Q3 2021 | -0.3x | Net Cash |
| Q2 2021 | -0.1x | Net Cash |
| Q1 2021 | -0.3x | Net Cash |
FLGT has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
FLGT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.9 | Neutral |
| Stochastic | 79.5 | Neutral |
FLGT's weekly RSI is 65 (neutral) and its Stochastic is 79 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
FLGT PE vs Healthcare Sector
| Metric | FLGT | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
FLGT has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
FLGT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $21.8 | 14% above |
| 20 week MA | $20.6 | 21% above |
| 50 week MA | $20.5 | 22% above |
| 100 week MA | $20.4 | 22% above |
| 200 week MA | $23.7 | 4.9% above |
FLGT has climbed back above all five of its weekly moving averages, and it's now 4.9% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
FLGT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $13.2 | $45.8 | +246% |
| 2021 | $45.8 | $100.2 | +119% |
| 2022 | $100.2 | $30.3 | -70% |
| 2023 | $30.3 | $28.9 | -4.7% |
| 2024 | $28.9 | $18.4 | -36% |
| 2025 | $18.4 | $26.7 | +45% |
| 2026 YTD | $26.7 | $24.9 | -7% |
FLGT's yearly returns have swung widely, from +246% in 2020 to −70% in 2022. It's down 7% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over FLGT on returns for 2026, with the stronger performance.